|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using the s.c. model, mice were monitored weekly for weight loss, tumor volume (TV) and serum PSA.
|
31767941 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LNCaP-cl1 had higher PSA expression but lower invasiveness and tumor growth potential than LNCaP-cl5.
|
24604720 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A Cox proportional hazards model, using the composite end point of a rising PSA or relapse, was performed with ploidy categorized as diploid, near-diploid, and nondiploid; pretreatment PSA, DNA ploidy, and tumor grade were found to be independent prognostic factors.
|
7511039 |
1994 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Prostate cancer was used as a paradigm because this tumor type is reliant at all stages of the disease on androgen receptor (AR) signaling, and cyclin D1 has been shown to negatively modulate AR-dependent expression of prostate-specific antigen (KLK3/PSA).
|
21212260 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed this panel to be an independent and superior predictor compared to current clinical predictors such as prostate specific antigen at diagnosis or the percent of tumor positive cores in the initial biopsy.
|
27545574 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Elevated serum PSA (> 4 ng/ml) is a tumor marker for prostatic cancer and benign prostatic hypertrophy; increasing serum PSA over time is indicative of metastatic disease.
|
11241552 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, the in vivo experiments demonstrated that MSC.scFv-Fdt-tBid significantly inhibited γ-SM-positive tumor growth without toxic side effects.
|
28529067 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was a statistically significant difference between ER/PR with PSA level and telomerase activity in tumor tissues (p < 0.05).
|
22329196 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ANXA2 and PSA proteins measured from biopsy tumour regions are unlikely to be good biomarkers for prediction of the clinical outcome of prostate cancer presenting with apparently localized disease.
|
29187477 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we show that immunization of mice with Ad5-PSA induced PSA-specific cellular and humoral immunity that was protective against a subcutaneous challenge with RM11 prostate cancer cells expressing PSA (RM11psa), but not mock-transfected RM11 tumor cells (RM11neo).
|
11745487 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A combination of high preoperative serum PSA and high expression of TMPRSS2-ERG could be promising in distinguishing those tumors that are aggressive and life-threatening.
|
27630329 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This was accompanied by a decline in serum prostate-specific antigen levels as well as a decrease in AR levels and mitoses in the tumors.
|
25375370 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RT±ADT cases (n=339) were matched with an equal number of RP cases by propensity scoring based on age, preoperative prostate-specific antigen, clinical tumor stage, biopsy Gleason score, and Charlson Comorbidity Index (CCI).CSM and OCM were co-primary endpoints.
|
28279064 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It consists of doxorubicin (Dox) conjugated to a prostate specific antigen (PSA)-cleavable peptide that can be selectively activated by secreted PSA at the tumor site.
|
30802065 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Low risk inclusion criteria included PSA < 10 ng/ml, cT1c or cT2a, Grade Group (GG) 1, < 3 positive cores, and < 50% tumor in a single core with the majority having a PSA density of < 0.15.
|
31014300 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LINC01296 expression was correlated with preoperative prostate specific antigen (<i>P</i>=0.002), lymph-node metastasis (<i>P</i>=0.035), Gleason score (<i>P</i><0.001), and tumor stage (<i>P</i>=0.036).
|
28392705 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Clinical indicators of aggressive prostate cancer behaviour such as PSA levels, PSA doubling time or the Gleason score of the primary tumour, as well as the androgen deprivation therapy, radiation therapy or chemotherapy status are not related to measured tracer uptake.
|
29044297 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Elevated NKX3.1 expression significantly correlated with tumor volume and serum prostate specific antigen (PSA) level in the NKX3.1 overexpression group (p<0.05).
|
10688034 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Serum PSA and tumor volumes were higher in men with undetectable versus detectable tissue abiraterone at prostatectomy (median 0.10 vs. 0.03 ng/dL, <i>P</i> = 0.02; 1.28 vs. 0.44 cc, <i>P</i> = 0.09, respectively).
|
28389510 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA (hK3) is one of the human kallikreins, and is the most useful tumor marker for prostate cancer screening, diagnosis, prognosis and monitoring. hK2, another prostate-specific kallikrein, has also been proposed as a complementary prostate cancer biomarker.
|
15911097 |
2005 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings suggest that CYP1B1 and PSA variants may affect the risk of prostate cancer and tumor aggressiveness.
|
16172228 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Within patients with detectable PSA, pathologic stage ≥ pT3a (HR 2.71; p < 0.029) and to received adjuvant androgen deprivation therapy (ADT) due to bad prognosis tumors (HR 13.36; p < 0.001) were associated with CR.Overall 14 (0.56%) died of PCa.
|
29243074 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, when Aza-CR was chronically administered (20 days), this treatment resulted in marked decrease in tumor cell proliferation with significant increase in AR and PSA protein levels.
|
18324645 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
No patient achieved a PSA reduction or a measurable tumor response.
|
27826729 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PCA3 gene expression discriminates LN metastasis and might outperform PSA gene activity in reflecting tumor cell burden in pelvic LNs of PCa patients.
|
25769446 |
2015 |